Source: International Congress 2017 – Novel studies on bronchodilators and cough
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Calzetta (Roma, Rm, Italy). Protein tyrosin kinase and KCa++ cannel: two faces of the same coin in LABA/LAMA synergy. 4407

Member's Comments

No comment yet.

Related content which might interest you: Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries Source: Eur Respir J 2013; 41: 85-95 Year: 2013 Experience of using Janus kinase inhibitors in COVID-19 Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Hemaglutinin (HA) of H5N1 disturbs cAMP-dependent CFTR channel via activation of janus kinase 3 Source: Annual Congress 2009 - Translational models of lung disease Year: 2009 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis Source: ERS Lung Science Conference 2020 Year: 2020 A patient with a lazarus effect on tyrosine kinase inhibition Source: Virtual Congress 2020 – Lung cancer grand round Year: 2020 Kinase inhibitors Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Tyrosine Kinase Transmembrane Receptor alterations in NSCLC Source: ERS Research Seminar Year: 2015 Tyrosine kinase inhibitors beyond progression: never, intercalating or forever? Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies Year: 2015 Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Effect of fudosteine on mucin production Source: Eur Respir J 2008; 32: 1195-1202 Year: 2008 Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 beta2-Agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway Source: Eur Respir J 2010; 35: 647-654 Year: 2010 The inositol trisphosphate pathway mediates platelet-activating-factor-induced pulmonary oedema Source: Eur Respir J 2005; 25: 849-857 Year: 2005